Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis. - Université de Lille Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2022

Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.

Résumé

Multiple Sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system (CNS). Current management strategies suppress or modulate immune function, all with consequences and known side effects. They demonstrate a high level of success in limiting new relapses. However, the neurodegenerative process still affects both grey and white matter in the central nervous system. The sigma1 (S1R) ligand-regulated chaperone is implicated in many biological processes in various CNS-targeted diseases, acting on neural plasticity, myelination and neuroinflammation. Among the proteins involved in MS, S1R has therefore emerged as a promising new target. Standard and robust methods have been adopted to analyze the adsorption, distribution, metabolism, excretion (ADME) properties, safety pharmacology and toxicology of a previously synthetized simple benzamide-derived compound with nanomolar affinity for S1R, high selectivity, no cytotoxicity and good metabolic stability. The compound was also characterized as an agonist based on well-validated assays prior to in vivo investigations. Interestingly, we found that the oral administration of this compound resulted in an overall significant reduction in clinical progression in an MS experimental model. This effect is mediated through S1R action. Our results further suggest the potential use of this compound in the treatment of MS.
Fichier principal
Vignette du fichier
ijms-23-11893-v2.pdf (2.79 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04144548 , version 1 (28-06-2023)

Licence

Identifiants

Citer

Bénédicte Oxombre, Farima Madouri, Anne-Sophie Journe, Severine Ravez, Eloise Woitrain, et al.. Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.. International Journal of Molecular Sciences, 2022, International Journal of Molecular Sciences, 23 (19), pp.11893. ⟨10.3390/ijms231911893⟩. ⟨hal-04144548⟩
5 Consultations
14 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More